ライフサイエンスコーパス: thrombospondin 1

1 growth factor, insulin-like growth factor 2, thrombospondin 1.

2 ive expression of angiogenic inhibitors like thrombospondin-1.

3 ain, but they do not hetero-oligomerize with thrombospondin-1.

4 r soluble P-selectin, platelet factor 4, and thrombospondin-1.

5 responses to the matricellular glycoprotein thrombospondin-1.

6 IF-1alpha) and VEGF and a down-regulation of thrombospondin-1.

7 DL (oxLDL), cell-derived microparticles, and thrombospondin-1.

8 of both transforming growth factor-beta and thrombospondin-1.

9 o dependent and might have been regulated by thrombospondin-1.

10 rivative of the natural angiogenic inhibitor thrombospondin-1.

11 le guanylyl cyclase-cGMP signaling inhibitor thrombospondin-1.

12 the production of the angiogenesis inhibitor thrombospondin-1.

13 d its receptor on T cells, but also by Ab to thrombospondin-1.

14 the production of the angiogenesis inhibitor thrombospondin-1.

15 otably plasminogen activator inhibitor-1 and thrombospondin-1.

16 CD47 is a receptor for the secreted protein thrombospondin-1.

17 ding activity and structural similarities to thrombospondin-1.

18 tivities of recombinant signature domains of thrombospondin-1, -2, and -4 to interact with CD47 and m

19 ant protein containing functional domains of thrombospondin-1, 3TSR, have been shown to be necessary

20 l fibroblasts through the down-regulation of thrombospondin 1, a latent transforming growth factor-be

21 Additionally, thrombospondin-1, a naturally occurring inhibitor of ang

22 activity of nitric oxide (NO) is blocked by thrombospondin-1, a potent antagonist of NO/cGMP signali

23 ucose-responsive fragment of the promoter of thrombospondin-1, a potent antiangiogenic and proatherog

24 A SIRP-alpha antibody that blocks thrombospondin-1 activation of SIRP-alpha mitigated the

25 and downregulates the angiogenesis inhibitor thrombospondin-1, along with other members of the thromb

26 AME, the guanylyl cyclase inhibitors ODQ and thrombospondin-1 also abated IR-induced IL10 expression

27 Thrombospondin-1 also inhibits cGMP-mediated activation

28 Exogenous thrombospondin-1 also reverses the suppression by NO of

29 Thrombospondin-1 also stimulated phosphorylation of p47(

30 s related to decreased protein expression of thrombospondin-1, an antiangiogenic regulator.

31 Matricellular proteins such as SPARC, thrombospondin 1 and 2, and tenascin C and X subserve im

32 responsible for binding to LRP1, whereas the thrombospondin 1 and spacer domains are responsible in A

33 hough very similar, the signature domains of thrombospondin-1 and -2 differ in several potentially im

34 The following candidates, thrombospondin-1 and 5, alpha-1B-glycoprotein, serum amy

35 CD47 is a signaling receptor for thrombospondin-1 and an attractive therapeutic target be

36 Furthermore, the CD36-binding domain of thrombospondin-1 and anti-angiogenic peptides derived fr

37 dostatin (an angiogenesis inhibitor), or for thrombospondin-1 and basic fibroblast growth factor, con

38 ncreased expression levels of antiangiogenic thrombospondin-1 and inhibited S1177 phosphorylation of

39 responses by the matricellular glycoprotein thrombospondin-1 and is therefore assumed to be the rece

40 Therefore, thrombospondin-1 and its receptor CD47 may be useful tar

41 Interaction of thrombospondin-1 and its recombinant NoC1 domain with al

42 evels of two potent angiogenesis inhibitors, thrombospondin-1 and maspin, were lower compared to cont

43 at least in part through down-regulation of thrombospondin-1 and plasminogen activator inhibitor typ

44 Here, we report a novel interaction between thrombospondin-1 and SIRP-alpha on nonphagocytic cells.

45 treatment, rescued the induced expression of thrombospondin-1 and the defect in endothelial cell prol

46 can also be heterotypic-for example, between thrombospondin-1 and thrombospondin-5.

47 y high levels of the angiogenesis inhibitors thrombospondin-1 and TIMP-1.

48 that exogenous decorin induced expression of thrombospondin-1 and TIMP3, two powerful angiostatic age

49 Binding studies with isolated human thrombospondin-1 and various Hic domains suggest that th

50 progeny, platelets, are important sources of thrombospondins 1 and 2 and that these thrombopoietic ce

51 Thrombospondins 1 and 2 are members of a family of angio

52 , GFAP, inducible nitric oxide synthase, and thrombospondins 1 and 2 in DS astroglia.

53 Thrombospondins 1 and 2 were among the first natural ang

54 entified vascular endothelial growth factor, thrombospondins 1 and 2, and slit as mediators partially

55 al growth factor165, ADAMTS9 neither cleaved thrombospondins 1 and 2, nor bound vascular endothelial

56 vior such as CD44, CCNE2 (cyclin E2), THBS1 (thrombospondin 1), and CSPG2 (chondroitin sulfate proteo

57 nsforming growth factor-beta induced factor, thrombospondin 1, and platelet derived growth factor-C w

58 essel maturation, including PDGFb, TGF-beta, thrombospondin-1, and CXCL10; consistently, they were ch

59 argo, including von Willebrand factor (VWF), thrombospondin-1, and platelet factor 4.

60 crovascular endothelial cells interacts with thrombospondin-1, and this interaction is involved in mo

61 ocrine cancer, administration of endostatin, thrombospondin-1, and tumstatin peptides, as well as del

62 DEB fibroblasts decreased type XII collagen, thrombospondin-1, and Wnt-5A expression, reduced tumor c

63 roblasts led to increased type XII collagen, thrombospondin-1, and Wnt-5A, while reexpression of wild

64 Both thrombospondin-1- and CD47-dependent radiosensitization

65 In contrast to thrombospondin-1- and CD47-null cells, primary vascular

66 he annexin A6/LDL receptor-related protein 1/thrombospondin 1 (ANXA6/LRP1/TSP1) complex in tumor cell

67 al cells returned the antiangiogenic protein thrombospondin-1 as a common target of both miRNAs.

68 ve to wild-type mice, implicating endogenous thrombospondin-1 as a physiologic antagonist of NO-media

69 We now identify thrombospondin-1 as a potent antagonist of NO for regula

70 only CD47 is necessary for this activity of thrombospondin-1 at physiological concentrations.

71 Thrombospondin 1 binding to calreticulin-LRP1 signals re

72 Overall, these results suggest that thrombospondin-1 binding to SIRP-alpha on nonphagocytic

73 nding site but not by a peptide based on the thrombospondin-1-binding site.

74 Thrombospondin-1 bound in a heparin-inhibitable manner t

75 In cell-free experiments, thrombospondin-1 bound SIRP-alpha.

76 for proapoptotic proteins including p53 and thrombospondin-1, but p53 was unchanged, and thrombospon

77 ll type-specific regulation of production of thrombospondin-1 by high glucose.

78 ery of the endogenous angiogenesis inhibitor thrombospondin-1 by platelets may be a critical host res

79 and (3) a stimulatory role for thrombin, the thrombospondin-1/CD36 axis and cyclooxygenase 1 in subse

80 mia-reperfusion injury is exacerbated by the thrombospondin-1-CD47 system through inhibition of nitri

81 Therefore, thrombospondin-1/CD47 antagonists may have selective rad

82 on injury (IRI), which is exacerbated by the thrombospondin-1/CD47 pathway through inhibition of nitr

83 The thrombospondin-1 concentrations in ST-Elevation Myocardi

84 ncluding vascular endothelial growth factor, thrombospondin 1, connective tissue growth factor, hepat

85 ADAMTS13 constructs, we show that the first thrombospondin-1, Cys-rich, and spacer domains of ADAMTS

86 on of ancillary C-terminal disintegrin-like, thrombospondin-1, cysteine-rich, and spacer domains to b

87 The results demonstrate that noncatalytic thrombospondin-1/cysteine-rich/spacer domains are princi

88 Replacing the thrombospondin-1/cysteine-rich/spacer domains of ADAMTS5

89 nvolved in the angiogenic process, including thrombospondin 1, delta-like 4, BclII modifying factor,

90 The role of CD47 was determined using the thrombospondin-1-derived agonist peptide 4N1K and the CD

91 Thrombospondin-1 did not inhibit NO signaling in CD47-nu

92 2), MMP9 (matrix metallopeptidase 9), TSP1 (thrombospondin 1), etc.

93 These data demonstrate that thrombospondin-1 exerts CD47-dependent and -independent

94 Only the CD47-binding domain of thrombospondin-1 exhibits this activity.

95 c EPCs have phenotypic differences involving thrombospondin-1 expression compared with nondiabetic EP

96 loproteinase-1, matrix metalloproteinase-10, thrombospondin-1, extracellular matrix matricryptic frag

97 ondin-2 and -4 were less active than that of thrombospondin-1 for inhibiting binding of radiolabeled

98 Thus, release of thrombospondin-1 from alpha-granules during activation p

99 Recent evidence indicates that the thrombospondin 1 gene is up-regulated in patients with R

100 active form of AhR induced activation of the thrombospondin-1 gene promoter.

101 The anti-angiogenic effect of thrombospondin-1 has been shown to be mediated through b

102 Human thrombospondin 1 (hTSP-1) is a matricellular glycoprotei

103 The human matricellular glycoprotein thrombospondin-1 (hTSP-1) is released by activated plate

104 ical PspC molecule, with human matricellular thrombospondin-1 (hTSP-1).

105 te the major rapidly releasable reservoir of thrombospondin-1 in higher animals.

106 Deletion of tumstatin and thrombospondin-1 in mice lacking the p53 tumor suppresso

107 We have uncovered a novel role of thrombospondin-1 in modulating production and activation

108 The role of thrombospondin-1 in radiosensitization is specific becau

109 EBV addition did not induce IDO or thrombospondin-1 in T-DC cocultures, suggesting that the

110 sed the levels of the angiogenesis inhibitor thrombospondin-1 in the xenografts.

111 istic relation between NO/cGMP signaling and thrombospondin-1 in vascular smooth muscle cells to regu

112 enuated in vitro antiangiogenic responses to thrombospondin-1, including blockade of migration, tube

113 In rodent aortic rings, treatment with thrombospondin-1 increased the production of superoxide

114 ion of the powerful angiostatic glycoprotein Thrombospondin 1 independently of Beclin 1 transcription

115 CD47, CD36, and integrin-binding domains of thrombospondin-1 independently enhance the inflammasome-

116 nsplantations, we show that platelet-derived thrombospondin-1 is a critical negative regulator during

117 Thrombospondin-1 is a glycoprotein with multiple biologi

118 Thrombospondin-1 is a multifunctional protein interactin

119 Thrombospondin-1 is a stress protein typically secreted

120 Thrombospondin-1 is a trimeric, modular calcium-binding

121 , inhibition of T cell receptor signaling by thrombospondin-1 is mediated by CD47 and requires its mo

122 We now show that endogenous thrombospondin-1 is necessary for platelet aggregation i

123 Therefore, thrombospondin-1 is the dominant regulator of NO/cGMP si

124 ed previously that the matricellular protein thrombospondin-1 is upregulated in IRI.

125 of the most potent angiogenesis inhibitors, thrombospondin-1, is up-regulated in the platelets of tu

126 and retina from enucleated eyes of C57BL/6, thrombospondin-1 knockout (TSP-1KO), and TGF-beta2 recep

127 rotein containing the CD36 binding domain of thrombospondin-1 (known as the TSR domain) induced assoc

128 Finally, crossing the KrP transgene onto a thrombospondin-1 KO background reversed the vascular cha

129 -and-actin bundling when clustered either by thrombospondin-1, laminin, or antibody to the syndecan-1

130 nal tubular epithelial cells, treatment with thrombospondin-1 led to phosphorylation of SIRP-alpha an

131 Serum thrombospondin-1 level was significantly increased after

132 Further, this work implicates the use of thrombospondin-1 levels in platelets as an indicator of

133 PEDF overexpression suppressed thrombospondin-1 levels in vitro.

134 te (p < 0.02) but not with changes in plasma thrombospondin-1 levels.

135 is study, we investigate the function of the thrombospondin-1-like glycoprotein, Nel (neural epiderma

136 Physiological concentrations of thrombospondin-1 limit the induction by lipopolysacchari

137 s demonstrated by showing that LPA abrogated thrombospondin-1-mediated inhibition of neovascularizati

138 DAMTS-13 mutant lacking the second to eighth thrombospondin-1 motifs and the complement components C1

139 Disintegrin-like and Metalloproteinase with Thrombospondin-1 motifs) protein family, cleaves large p

140 Notably, thrombospondin-1 mRNA expression was significantly upreg

141 is a consequence of both increased levels of thrombospondin-1 mRNA in megakaryocytes, as well as incr

142 Thrombospondin-1 mRNA increased in 7- and 12-week-old ra

143 lasma levels of von Willebrand factor (VWF), thrombospondin-1, myeloperoxidase, ADAMTS-13, and active

144 NO/cGMP signaling could be detected only in thrombospondin-1-null cells.

145 responses to NO were preserved in irradiated thrombospondin-1-null hindlimbs.

146 We show here that soft tissues in thrombospondin-1-null mice are remarkably resistant to r

147 y of oxygen levels in the ischemic tissue of thrombospondin-1-null mice as measured by electron param

148 elve hours after 25-Gy hindlimb irradiation, thrombospondin-1-null mice showed significantly less cel

149 cking CD47 showed radioresistance similar to thrombospondin-1-null mice.

150 issue survival was significantly enhanced in thrombospondin-1-null mice.

151 Thrombospondin-1-null murine platelets fail to aggregate

152 tions of the NO synthase substrate arginine, thrombospondin-1-null platelets have elevated basal cGMP

153 in skeletal muscle perfusion was enhanced in thrombospondin-1-null relative to wild-type mice, implic

154 ed cGMP accumulation and mimic the effect of thrombospondin-1 on aggregation.

155 sis factor-related apoptosis-induced ligand, thrombospondin-1, optineurin, and palladin.

156 y to promote angiogenesis in the presence of thrombospondin-1 or -2.

157 marrow-derived macrophages that lack either thrombospondin-1 or CD47 exhibit diminished induction of

158 Blockade of thrombospondin-1 or CD47 provides local radioprotection

159 binding of radiolabeled signature domain of thrombospondin-1 or SIRPalpha (signal-regulatory protein

160 M organization, we find that accumulation of thrombospondin-1 or thrombospondin-5 puncta within cell-

161 pression levels of either tubulointerstitial thrombospondin-1 or transforming growth factor-beta desp

162 by antibodies, recombinant type 1 repeats of thrombospondin-1, or CD36-binding peptides was sufficien

163 putative latent TGFbeta1 activators include thrombospondin-1, oxidants, and various proteases.

164 nant C-terminal regions of thrombospondin-1, thrombospondin-1 peptides, or CD47 antibodies was also s

165 d messenger RNA expression of interleukin-6, thrombospondin-1, plasminogen activator inhibitor-1, and

166 Thrombospondin-1 prevents NO-mediated relaxation of prec

167 sferase 2 (POFUT2) was described for TSRs of thrombospondin-1, properdin, and F-spondin within the se

168 e evolved from cell-SELEX that can recognize thrombospondin-1 protein in human plasma samples.

169 design of an M55-aptasensor for quantifying thrombospondin-1 protein in plasma samples.

170 CD47 is a known thrombospondin-1 receptor but was not previously reporte

171 Ligation of the thrombospondin-1 receptor CD47 by recombinant C-terminal

172 of CD47 (an alphavbeta3 integrin coreceptor/thrombospondin-1 receptor) and integrins alphavbeta3 and

173 Thrombospondin-1 regulates inflammation by engaging seve

174 Thrombospondin-1 regulates nitric oxide (NO) signaling i

175 evels of another key antiangiogenic protein, thrombospondin-1, reinforcing its antitumor and antiangi

176 Furthermore, the endogenous ligand thrombospondin-1, responsible for the synaptogenic prope

177 In the absence of thrombospondin-1, retinal neovascular membranes are mark

178 h shear and static conditions, and exogenous thrombospondin-1 reverses this delay.

179 ng in ischemic soft tissues, suggesting that thrombospondin-1 signaling via its receptor CD47 could c

180 le cells, picomolar concentrations of native thrombospondin-1 similarly inhibited NO signaling in vas

181 Renal IRI upregulated the thrombospondin-1-SIRP-alpha signaling axis and was assoc

182 -898 mimics the antiangiogenic properties of thrombospondin-1, so we hypothesized that ABT-898 will p

183 ugh some fragments and peptides derived from thrombospondin-1 stimulate or inhibit platelet aggregati

184 l metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T), Cys-rich (C), and spacer (S) domai

185 ARID domain-dependent, BAF-A associations at THROMBOSPONDIN 1 (THBS1) led to the concomitant upregula

186 Thrombospondin 1 (THBS1) was recently shown to promote b

187 on of the TGF-beta-regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protei

188 Thrombospondin-1 (THBS1) is a large extracellular matrix

189 We examined thrombospondin-1 (THBS1, alias TSP-1) expression in huma

190 -regulated the potent angiogenesis inhibitor thrombospondin-1, thereby triggering a negative feedback

191 or CD47 by recombinant C-terminal regions of thrombospondin-1, thrombospondin-1 peptides, or CD47 ant

192 nhibition can be explained by the ability of thrombospondin-1 to disrupt the interaction between CD47

193 jury, possibly due to the stimulation of the thrombospondin-1-transforming growth factor-beta pathway

194 rtilage oligomeric matrix protein (COMP) and thrombospondin 1 (TSP-1) correlated moderately well with

195 Thrombospondin 1 (TSP-1) is a matricellular protein that

196 aneous somatic Ca2+ transients, synaptogenic thrombospondin 1 (TSP-1) release, and synapse formation.

197 Basal muscle expression of thrombospondin 1 (TSP-1) was approximately 900% greater

198 ial growth factor (VEGF), but high levels of thrombospondin 1 (TSP-1), predicted liver dysfunction af

199 n-associated protein, and its natural ligand thrombospondin 1 (TSP-1).

200 cluding Rho-activated kinase II (ROCKII) and thrombospondin 1 (TSP-1).

201 eptidomimetic of the anti-angiogenic protein thrombospondin-1 (TSP-1 PM).

202 sis through binding to the type 1 repeats of thrombospondin-1 (TSP-1) and activating Fyn tyrosine kin

203 grins) and ECM noncellular components [i.e., thrombospondin-1 (TSP-1) and fibronectin (FN)] seem to t

204 uced angiogenesis and elevated expression of thrombospondin-1 (TSP-1) and its receptor CD36, anti-ang

205 he capacity to bind the CD47-binding partner thrombospondin-1 (TSP-1) and that treatment of aged eryt

206 tion, the loss of p53 led to a deficiency in thrombospondin-1 (TSP-1) expression, a potent antiangiog

207 nteractions with proteins and proteoglycans, thrombospondin-1 (TSP-1) functions at the interface of t

208 The N700S polymorphism of thrombospondin-1 (TSP-1) has been identified as a potent

209 ntact dependent, leading to up-regulation of thrombospondin-1 (TSP-1) in DCs.

210 ine fashion by stimulating the expression of thrombospondin-1 (Tsp-1) in fibroblasts present in both

211 Thrombospondin-1 (TSP-1) inhibits angiogenesis and activ

212 Thrombospondin-1 (TSP-1) inhibits growth factor signalin

213 Thrombospondin-1 (TSP-1) is a glycoprotein considered as

214 Thrombospondin-1 (TSP-1) is a large extracellular matrix

215 Thrombospondin-1 (TSP-1) is a major activator of latent

216 Thrombospondin-1 (TSP-1) is a multifunctional protein wh

217 Thrombospondin-1 (TSP-1) is a multimodular glycoprotein

218 cular permeability and angiogenesis, whereas thrombospondin-1 (TSP-1) is a potent angiogenic inhibito

219 Thrombospondin-1 (TSP-1) is an endogenous inhibitor of a

220 Thrombospondin-1 (TSP-1) is an endogenous inhibitor of a

221 Here we show TGF-beta activation by thrombospondin-1 (TSP-1) is both required and sufficient

222 he expression of an anti-angiogenic protein, thrombospondin-1 (TSP-1) is down-regulated in the prosta

223 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic f

224 Here we show that thrombospondin-1 (TSP-1) prevents cAMP/protein kinase A

225 d decrease in p53 expression, thus enhancing thrombospondin-1 (TSP-1) release from EC and reducing FG

226 of atherogenesis, we considered the role of thrombospondin-1 (TSP-1), a matricellular protein releas

227 Thrombospondin-1 (TSP-1), a potent antiangiogenic and pr

228 Increasing evidence suggests thrombospondin-1 (TSP-1), a potent proatherogenic matric

229 ntiangiogenic factors, including endostatin, thrombospondin-1 (TSP-1), and pigment epithelium-derived

230 nd re-expression of a synaptogenic molecule, thrombospondin-1 (TSP-1), apart from supporting neuronal

231 xtensive in vitro and in vivo validations on thrombospondin-1 (TSP-1), because it has been previously

232 ent derived from the second type-1 repeat of thrombospondin-1 (TSP-1), is known to possess antiangiog

233 The matricellular protein, thrombospondin-1 (TSP-1), is prominently expressed durin

234 mice deficient in tumstatin, endostatin, or thrombospondin-1 (TSP-1), to address the role that these

235 iptionally down-regulating the production of thrombospondin-1 (TSP-1)--known earlier for both its ant

236 spectrometry helped pinpoint this factor as thrombospondin-1 (TSP-1).

237 y involving the TGF-beta-activating protease thrombospondin-1 (TSP-1).

238 a receptor for the anti-angiogenic molecule thrombospondin-1 (TSP-1).

239 mposed of the three type-1 repeats (3TSR) of thrombospondin-1 (TSP-1).

240 n-8 (IL-8), and on an antiangiogenic factor, thrombospondin-1 (TSP-1).

241 muscle cells that mediates up-regulation of thrombospondin-1 (TSP-1).

242 ic destruction of the antitumorigenic factor thrombospondin-1 (Tsp-1).

243 on of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1).

244 ts high levels of the angiogenesis inhibitor thrombospondin-1 (TSP-1).

245 The Nel protein contains an N-terminal thrombospondin-1 (TSP-N) domain, five cysteine-rich doma

246 ssion of two endogenous vascular regulators, thrombospondins 1 (TSP-1) and 2 (TSP-2).

247 tein expression of anti-angiogenic peptides (thrombospondin-1, TSP-1; and endostatin) as well as pro-

248 le expressed significantly reduced levels of thrombospondin 1 (TSP1) (P = 0.042) and increased levels

249 onic opiate treatment of rats down-regulates thrombospondin 1 (TSP1) expression in the nucleus accumb

250 Thrombospondin 1 (TSP1) expression is increased in diabe

251 Thrombospondin 1 (TSP1) has been suggested as a counter

252 Thrombospondin 1 (TSP1) induces focal adhesion disassemb

253 The matricellular protein thrombospondin 1 (TSP1) regulates cell adhesion and moti

254 e levels of an extracellular matrix protein, thrombospondin 1 (TSP1), an angiogenesis inhibitor.

255 Thrombospondin 1 (TSP1), an oligomeric matrix protein, i

256 variety of endogenous inhibitors, including thrombospondin 1 (TSP1).

257 /-) manifested higher expression of CTGF and thrombospondin 1 (TSP1).

258 s 1, IV and XVIII as well as fibronectin and thrombospondin 1 (TSP1).

259 lated with downregulation of anti-angiogenic thrombospondin-1 (Tsp1) and related proteins, such as co

260 -regulated STAT3 phosphorylation, astrocytic thrombospondin-1 (TSP1) and synaptic low-density lipopro

261 njury via a mechanism mediated by astrocytic thrombospondin-1 (TSP1) and synaptic low-density lipopro

262 Thrombospondin-1 (TSP1) and TSP2 are matricellular prote

263 Thrombospondin-1 (TSP1) binding to calreticulin (CRT) on

264 Thrombospondin-1 (TSP1) binding to calreticulin (CRT) on

265 Here we report that soluble thrombospondin-1 (TSP1) binds to the extracellular part

266 Thrombospondin-1 (TSP1) can inhibit angiogenic responses

267 The N-terminal thrombospondin-1 (TSP1) domain forms an unexpectedly ext

268 from mice lacking the angiogenesis inhibitor thrombospondin-1 (TSP1) exhibit exaggerated angiogenic r

269 Plasmin (PLS) and thrombospondin-1 (TSP1) have been studied individually a

270 We confirm upregulation of thrombospondin-1 (TSP1) in Id cDKO hearts.

271 s calcineurin/NFATc1-dependent expression of thrombospondin-1 (Tsp1) in lung endothelial cells to dri

272 Thrombospondin-1 (TSP1) inhibits angiogenesis, in part,

273 Thrombospondin-1 (TSP1) is a multifunctional matricellul

274 The secreted protein thrombospondin-1 (TSP1) limits NO-stimulated blood flow

275 Thrombospondin-1 (TSP1) limits the angiogenic and vasodi

276 nvolved in the regulation of angiogenesis is thrombospondin-1 (TSP1), a matricellular glycoprotein kn

277 that, upon CREB activation, HDAC2 represses thrombospondin-1 (TSP1), a potent angiogenesis inhibitor

278 ntiation 1 (Id1), which negatively regulates thrombospondin-1 (TSP1), an inhibitor of angiogenesis.

279 ited tumor angiogenesis via the induction of Thrombospondin-1 (TSP1), and consequently suppressed tum

280 in the levels of the angiogenesis inhibitor thrombospondin-1 (TSP1), but the mechanisms underlying t

281 by JHDM1D-mediated epigenetic regulation of thrombospondin-1 (TSP1), forming a JHDM1D/TSP1/TGF-beta/

282 d to be an inhibitory signaling receptor for thrombospondin-1 (TSP1), the molecular mechanism for tra

283 he hypothesis that the matricellular protein thrombospondin-1 (TSP1), through binding to and activati

284 ently, we reported that the secreted protein thrombospondin-1 (TSP1), through its cell surface recept

285 We recently found that leukocytes from thrombospondin-1 (TSP1)-deficient mice exhibit significa

286 lating erythrocyte microparticles (MPs), and thrombospondin-1 (TSP1).

287 nsin II induce the latent TGF-beta activator thrombospondin-1 (TSP1).

288 ine in the levels of angiogenesis inhibitor, thrombospondin-1 (TSP1).

289 Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy

290 EOC cells with a recombinant version of the thrombospondin-1 type I repeats (3TSR) induced more apop

291 TS (A Disintegrin and metalloproteinase with thrombospondin-1 type repeats) family of enzymes have be

292 The Ser-700 variant thrombospondin-1 was conformationally more labile than t

293 The KD value of the aptamer M55 binding to thrombospondin-1 was determined as 0.5 +/- 0.2 muM with

294 Inhibition of T cell receptor signaling by thrombospondin-1 was lost in CD47-deficient T cells that

295 binding selectivity, the signature domain of thrombospondin-1 was more potent than those of thrombosp

296 Levels of VEGF, E-selectin, and thrombospondin-1 were not associated with clinical outco

297 Plasma levels of VEGF, E-selectin, and thrombospondin-1 were obtained serially.

298 ty group box-1 protein, chemokine CXCL4, and thrombospondin-1 were significantly higher in patients w

299 Here, we found that both CD47 and its ligand thrombospondin-1 were upregulated after renal IRI in mic

300 telet-derived growth factor, collagen I, and thrombospondin-1) were higher in PEDF-null mice at basel